Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Clinical Trial
Official title:
Stratified Therapy on Pediatric AAGN Based on Risk Assessment-A Prospective, Multicenter, Open, Tendentious Matched Control Clinical Study
Clinical information of children with ANCA-associated nephritis admitted to Children's Hospital Affiliated to Chongqing Medical University and partner centers from January 1, 2023 to December 31, 2023 was collected: To evaluate and compare the differences in survival, renal outcomes, and adverse reactions in children with ANCA-associated nephritis given different interventions according to the revised PARRG risk stratification, and to evaluate the superiority of ANCA-associated nephritis given according to the revised PARRG risk stratification. (2) To evaluate the efficacy and safety of glucocorticoid combined with rituximab and cyclophosphamide as induction regimen in high-risk group and glucocorticoid combined with rituximab as induction regimen in children with ANCA-associated nephritis (AAGN) in low and middle risk group based on PARRG risk stratification
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06316076 -
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
|
Phase 1 | |
| Completed |
NCT05988008 -
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
|
Phase 1 | |
| Active, not recruiting |
NCT02198248 -
Low-dose Glucocorticoid Vasculitis Induction Study
|
Phase 4 | |
| Completed |
NCT06004960 -
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT06350110 -
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01275287 -
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
|
Phase 2 | |
| Not yet recruiting |
NCT04871191 -
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
|
Phase 2 | |
| Recruiting |
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06226662 -
Study of NM8074 in Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
|
Phase 2 | |
| Terminated |
NCT02749292 -
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
|
Phase 4 | |
| Terminated |
NCT02294344 -
The Clinical Efficacy of DFPP in Patients With AAGN
|
N/A | |
| Withdrawn |
NCT01275274 -
Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
|
Phase 2 | |
| Completed |
NCT06004947 -
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
|
Phase 1 | |
| Recruiting |
NCT03323476 -
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
|
Phase 3 | |
| Completed |
NCT05988021 -
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
|
Phase 1 | |
| Terminated |
NCT01934504 -
Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)
|
N/A | |
| Recruiting |
NCT06056921 -
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
|
Phase 1 | |
| Not yet recruiting |
NCT02180126 -
Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation
|
N/A | |
| Recruiting |
NCT06294236 -
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
|
Phase 1 | |
| Not yet recruiting |
NCT06379646 -
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
|
N/A |